Continuous Glucose Monitoring: A Physician's Guide to Metabolic Health Optimization

At a Glance

Continuous glucose monitoring was once the exclusive domain of type 1 diabetics and intensive-care units. That changed when miniaturized biosensors entered the consumer market and researchers began applying CGM data to metabolic phenotyping in people without diabetes. What emerged challenged decades of clinical assumption: fasting glucose and HbA1c — the two cornerstones of routine metabolic screening — miss a substantial fraction of metabolic dysfunction. In a landmark 2018 Stanford study, roughly 25% of participants without any diagnosis of diabetes showed post-meal glucose spikes into the prediabetic range on a sensor but looked entirely normal on standard labs. For a practice focused on early intervention and optimized longevity, the implications are profound.

Why Standard Glucose Labs Fall Short

The HbA1c Blind Spot

HbA1c reflects average red blood cell glycation over approximately 90 days. The problem is the word average. A patient who oscillates between 60 and 240 mg/dL can return the same HbA1c as someone whose glucose sits steadily at 100 mg/dL. The oscillating patient is generating far more oxidative stress, advanced glycation end-products (AGEs), and endothelial damage — yet both read “normal.”

HbA1c is further confounded by haematological variables. Iron deficiency anaemia, haemolytic conditions, haemoglobin variants (HbS, HbC), and even altitude artificially raise or lower the reported value independent of true glycaemic status. In complex patients — the chronic infection population, post-COVID patients with microclot-driven haemolysis, patients on iron IV — HbA1c becomes frankly unreliable.

Fasting Glucose Is a Single Frame

A 12-hour fasted glucose value captures metabolism during physiological inactivity with suppressed postprandial signalling. It says almost nothing about how that individual responds to a meal, what their nocturnal nadir looks like, or whether stress-induced cortisol spikes are driving glucose into the 160s at 4 a.m. I have seen patients with fasting glucose of 82 mg/dL routinely hitting 185 mg/dL after oatmeal — metabolically they are prediabetic, but no standard lab would flag them.

What CGM Actually Measures

Modern sensors — the Abbott FreeStyle Libre 3 and Dexterity G7 being the most clinically validated — use enzymatic electrochemical detection in interstitial fluid. There is a physiological lag of 5–15 minutes between blood glucose and interstitial glucose, which matters during rapid excursions but is inconsequential for the population-level patterns we are interpreting.

The device outputs a glucose trace every 1–5 minutes over 14 days, generating roughly 4,000 data points per wear period. From this trace, the clinician can extract:

Time in Range (TIR): Percentage of readings between 70 and 140 mg/dL. In non-diabetic longevity optimization, I target > 90%. A TIR below 80% in an otherwise healthy patient is an indication for dietary restructuring.

Glucose Variability (Standard Deviation): High variability — even when the mean looks normal — predicts cardiovascular risk independently of mean glucose. A 2019 meta-analysis in Diabetes Care found that each 1 mg/dL increase in glucose SD was associated with a 1.4% increase in all-cause mortality in non-diabetic subjects.

Post-Meal Peaks: The 1-hour and 2-hour post-meal peaks are the most actionable data points for dietary modification. A peak above 140 mg/dL triggers a significant insulin secretory response and initiates lipid oxidation changes that persist for hours.

Nocturnal Patterns: The night trace separates cortisol-mediated dawn phenomenon from reactive hypoglycaemia from genuine hypoglycaemia unawareness — three distinct conditions requiring completely different management.

Reading the CGM Trace: Clinical Patterns I See Regularly

Pattern 1: The “Healthy” Patient with Postprandial Hyperglycaemia

Fasting glucose 84, HbA1c 5.3%, but the CGM shows a standard breakfast driving glucose to 172 mg/dL at 45 minutes, returning to baseline by 2.5 hours. Insulin response is intact — the return is smooth — but the peak exposure is prediabetic. These patients invariably improve with: (1) breakfast composition change (eliminating refined carbohydrate), (2) a 10-minute post-meal walk, (3) consideration of berberine 500 mg before the meal if dietary modification alone is insufficient within 4 weeks.

Pattern 2: Dawn Phenomenon

Glucose rises from 78 to 112 mg/dL between 4 and 7 a.m. without any food intake. This is normal physiology amplified — cortisol and growth hormone peaks drive hepatic glucose output. In patients with elevated fasting glucose (90–100 mg/dL), dawn phenomenon often accounts for 30–50% of the elevation. Intervention: time-restricted eating with an earlier eating window (8 a.m.–4 p.m. or 10 a.m.–6 p.m.) can substantially blunt this.

Pattern 3: Reactive Hypoglycaemia

A large carbohydrate load drives glucose to 165 mg/dL, an aggressive insulin spike follows, and by 2.5 hours glucose is at 62 mg/dL with the patient reporting fatigue, brain fog, and carbohydrate craving. This pattern — the postprandial crash — is extremely common in patients presenting with afternoon energy slumps, poor cognitive function in the late morning, or difficulty with fasting. It resolves rapidly with low-glycaemic-index eating, protein prioritisation at breakfast, and addressing underlying insulin resistance.

Pattern 4: Stress-Driven Nocturnal Spikes

In high-cortisol patients — Lyme disease patients, post-COVID patients, adrenal dysregulation — glucose rises to 110–130 mg/dL at 2–4 a.m. without food intake. This is almost exclusively cortisol-mediated. The treatment is not glucose management but cortisol normalisation: DHEA repletion, adaptogen protocols, addressing the underlying inflammatory driver.

Pattern 5: Flat, Low Variability Trace

Occasionally the CGM reveals enviably stable glucose — fasting at 80, post-meal peaks below 120, SD of 8 mg/dL. These patients have excellent insulin sensitivity. In longevity-focused patients, this pattern correlates strongly with metabolic youth regardless of chronological age, and it is associated with lower biological age on epigenetic testing.

Practical Protocol: How I Use CGM in Clinical Practice

Who Gets a CGM?

In my practice, I recommend a 14-day CGM wear for any patient with:

• Fasting glucose ≥ 90 mg/dL
• HbA1c ≥ 5.4%
• BMI ≥ 25 or visceral adiposity on examination
• Unexplained fatigue, post-meal energy crashes, or brain fog
• Cardiovascular risk factors (hypertension, dyslipidaemia, family history)
• Chronic inflammatory conditions (Lyme, post-COVID, autoimmunity) where glucose dysregulation is a perpetuating factor
• Any patient enrolled in a longevity or biological age optimisation programme

The 14-Day Protocol

Days 1–3: Habitual baseline. Patient eats and lives normally. No dietary modifications. This establishes the metabolic phenotype.

Days 4–7: Targeted food challenges. Patient tests specific foods of interest: oats, white rice, sourdough bread, fruit, pasta. Each food is eaten in isolation (to isolate the glycaemic response) and data is recorded in a food journal alongside the CGM trace.

Days 8–11: Intervention phase. Based on findings from days 4–7, introduce modifications: food sequencing (vegetables first, protein second, carbohydrates last), post-meal walks, resistant starch, vinegar with meals. Measure the impact on peak and variability.

Days 12–14: Lifestyle variable testing. Test effects of: sleep deprivation (night of 5 versus 7.5 hours), stress (a difficult conversation, competitive exercise), cold exposure, fasting duration, and alcohol.

By day 14, the patient has a detailed personalised metabolic map that no blood test could have generated.

CGM in the Context of Complex Disease

Lyme and Chronic Infection

Chronic Borrelia infection drives a low-grade pro-inflammatory state that impairs insulin signalling at the receptor level. IL-6 and TNF-α — chronically elevated in active Lyme — are direct insulin antagonists. This means Lyme patients with previously normal glucose regulation can develop significant postprandial spikes during active disease. Tracking glucose on CGM during treatment allows us to identify when inflammatory burden is improving (glucose variability typically normalises before subjective symptom improvement) and to adjust nutritional support accordingly.

Post-COVID and Microclot Pathology

Post-COVID patients deserve particular attention. SARS-CoV-2 directly infects pancreatic beta cells via ACE2 receptors, and a subset of patients develops measurable insulin secretory defects post-infection. Additionally, microclots impair tissue perfusion — including in skeletal muscle, the major site of post-meal glucose disposal. CGM in post-COVID patients frequently reveals elevated postprandial peaks and delayed glucose return to baseline that is disproportionate to their apparent health status.

Thyroid Dysfunction

Hypothyroid patients have slowed glucose disposal kinetics. Hyperthyroid patients show exaggerated post-meal peaks with rapid return. In patients on thyroid hormone optimisation, CGM serves as a sensitive real-world marker of thyroid hormone adequacy — often more informative than TSH in the short term.

Supplements and Lifestyle Interventions Validated by CGM

The advantage of CGM for patient engagement is immediate feedback. Abstractions like “insulin resistance will improve your risk profile in 10 years” are difficult to motivate action. Watching glucose peak at 170 versus 120 after the same meal depending on whether a 10-minute walk was taken is viscerally convincing. CGM has become the most powerful patient activation tool in my practice.

Interventions with robust CGM-validated benefit include:

• Post-meal walking (10–15 min): Reduces postprandial peak by 15–30% via contraction-mediated GLUT4 translocation in skeletal muscle. This is one of the most pharmacologically potent glucose-lowering interventions available without drugs.
• Food sequencing (fibre/protein first): Reduces peak by 20–40% compared to carbohydrate-first eating. Mechanism: slowed gastric emptying and reduced amylase activity in the presence of viscous fibre.
• Berberine (500 mg before carbohydrate-rich meals): AMPK activation reduces hepatic glucose output and improves peripheral glucose uptake. In my CGM data, berberine reliably reduces postprandial peaks by 25–45 mg/dL in patients with mild to moderate insulin resistance.
• Apple cider vinegar (1–2 tbsp with meals): Acetic acid inhibits disaccharidase activity, slowing glucose absorption. Effect is modest (10–15 mg/dL peak reduction) but consistent and well tolerated.
• Adequate sleep (> 7.5 hours): A single night of 5-hour sleep increases next-day postprandial glucose peaks by 20–30 mg/dL through cortisol-mediated insulin resistance. CGM makes this relationship undeniable.
• Resistance training: Regular resistance training is among the most durable interventions for improving TIR, through sustained increases in skeletal muscle GLUT4 expression.

Interpreting CGM Data: What to Bring to Your Physician

When presenting CGM data for clinical review, the most informative elements are:

1. The ambulatory glucose profile (AGP) report — a standardised visualisation showing the median trace with 10th–90th percentile bands. Most CGM apps export this as a PDF.
2. TIR percentage and the breakdown of time above range (TAR) and time below range (TBR)
3. The highest single-day peak and the meal that caused it
4. The nocturnal trace for any patient with sleep complaints or morning fatigue
5. Glucose coefficient of variation (CV) — a value above 36% warrants clinical attention even in non-diabetic patients

Related Articles

• How to Read Your Functional Medicine Blood Panels — understanding the full metabolic picture beyond glucose
• Berberine for Blood Sugar: Clinical Evidence and Dosing — the CGM-validated supplement for glucose management
• Longevity Blood Panel: What I Check and Why — where CGM data fits within comprehensive metabolic assessment
• Metformin vs Berberine: A Physician’s Comparison — pharmacological options when lifestyle optimisation is insufficient
• Reading Your Hormone Panel: DHEA, Cortisol, and Metabolic Risk — how cortisol patterns appear on CGM and what to do about them

References

1. Danne T, et al. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017;40(12):1631–1640. PMID: 29162584
2. Kohnert KD, et al. Glycemic Variability and Cardiovascular Risk in Type 2 Diabetes: A Systematic Review. Diabetes Metab Syndr. 2019;13(1):584–592. PMID: 30641762
3. Hall H, et al. Glucotypes Reveal New Patterns of Glucose Dysregulation. PLOS Biol. 2018;16(7):e2005143. PMID: 30040822
4. Freckmann G, et al. Continuous Glucose Profiles in Healthy Subjects Under Everyday Life Conditions. J Diabetes Sci Technol. 2007;1(5):695–703. PMID: 19885137
5. Ceriello A, Monnier L, Owens D. Glycaemic variability in diabetes: clinical and therapeutic implications. Lancet Diabetes Endocrinol. 2019;7(3):221–230. PMID: 30528094
6. Gutierrez JL, et al. Vinegar Ingestion at Bedtime Moderates Waking Glucose Concentrations in Adults With Well-Controlled Type 2 Diabetes. Diabetes Care. 2007;30(11):2814–2815. PMID: 17712024
7. DiPietro L, et al. Three 15-min Bouts of Moderate Postmeal Walking Significantly Improves 24-h Glycemic Control in Older People at Risk for Impaired Glucose Tolerance. Diabetes Care. 2013;36(10):3262–3268. PMID: 23775814